Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of several investigational long-acting antibody treatments, both alone and in combination, for adults with moderately to severely active ulcerative colitis UC. This Phase 2 platform study involves multiple centers and aims to improve treatment options for this condition by comparing different therapies. The study consists of two parts. Part A was an open-label phase assessing safety and early effectiveness of three monotherapies, which completed enrollment in April 2026. Part B is currently enrolling and is a randomized, placebo-controlled phase testing three monotherapies and three combination therapies against placebo. Participants will receive intravenous induction and subcutaneous maintenance treatments, with different dosing regimens evaluated over time. Participants will be monitored through regular assessments including endoscopy and histology to measure disease activity and response. The main outcomes include clinical remission and histologic improvement after 12 weeks, with longer-term remission assessed up to 48 weeks. Safety and efficacy data will be collected throughout, with treatment duration and follow-up determined by study protocol. The total study completion is expected by March 2028.
Actively Recruiting
Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.
Actively Recruiting
Researchers are studying an experimental drug called linvoseltamab in adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplantation. The study aims to compare the effects and safety of linvoseltamab combined with standard treatment against the standard treatment alone. This is a Phase 3 randomized, open-label trial sponsored by the European Myeloma Network B.V. Participants will receive either the combination of daratumumab, lenalidomide, dexamethasone, and linvoseltamab or continued treatment with daratumumab, lenalidomide, and dexamethasone alone. Treatments will be given according to the study protocol, and participants will be randomly assigned to one of these two groups. The study will continue for up to 11 years to assess long-term effects. During the study, participants will undergo various assessments including measurements of minimal residual disease MRD, progression-free survival, overall survival, and response rates. Quality of life will also be evaluated using standardized questionnaires. Safety will be closely monitored by tracking adverse events and laboratory tests. Participants will be followed up for up to 11 years, with regular visits to assess disease status and treatment impact.
Actively Recruiting
Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease CD in a multinational, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. This trial includes three sub-studies designed to assess treatment effects through different induction periods and includes a follow-up for some participants. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The study duration may last up to 35 weeks, including a screening period of up to 5 weeks, a 12-week induction period in each sub-study, and a 6-week follow-up period for those not entering maintenance. Participants who continue to the pivotal maintenance study have up to 8 or 15 scheduled visits depending on their sub-study. During the study, participants undergo regular assessments including clinical remission and endoscopic response measured by Crohns Disease Activity Index CDAI, Simple Endoscopic Score for Crohns Disease SES-CD, and patient-reported outcomes. Researchers also monitor safety through adverse event tracking, serum drug levels, and antibody formation. The primary outcomes focus on remission and response at 12 weeks, with additional secondary outcomes and safety evaluations throughout the study.
Actively Recruiting
Researchers are studying the effects of duvakitug in adults and older teenagers with moderately to severely active Ulcerative Colitis UC, a condition causing inflammation in the colon. This Phase 3 clinical trial is designed to evaluate both the effectiveness and safety of this treatment compared to placebo injections. The study is randomized, double-blind, and takes place at multiple international centers to ensure reliable results. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The trial includes a screening period followed by a 12-week initial treatment phase, with an additional 12-week extended induction period for those who do not respond initially. Participants who do not join the maintenance study will have a 45-day follow-up visit after completing the induction phases. During the study, participants will attend up to 8 visits in the initial treatment phases and up to 15 visits if they continue to the extended induction period. Researchers will assess clinical remission rates, endoscopic improvement, symptom responses, quality of life scores, and safety outcomes such as adverse events and immune responses to the drug. The total study participation may last up to 35 weeks, allowing close monitoring of health and treatment effects throughout.
Actively Recruiting
Researchers are studying patients with hormone receptor-positive, HER2-negative early breast cancer HRHER2- EBC who are at high risk of their cancer returning. This observational study includes both past and future phases to assess the clinical and pathological features, treatment choices, and outcomes of patients treated with CDK46 inhibitors ribociclib or abemaciclib combined with endocrine therapy in the adjuvant setting. The study also focuses on patients whose cancer returned during or within 12 months after finishing this adjuvant treatment. Participants are those who have started or are starting adjuvant treatment with ribociclib or abemaciclib along with endocrine therapy since January 1, 2021. This study does not involve assigning treatments but observes patients receiving these therapies in real-world settings. It gathers data on treatment patterns, recurrence, and clinical outcomes without altering patient care. During the study, researchers will collect and analyze data on patient health, tumor characteristics, and treatment responses. They will track invasive disease-free survival over 3 years as the main outcome, along with distant relapse-free survival, progression-free survival, and overall survival up to 5 years. Participants will provide consent for their data to be used, and their health status will be monitored through routine medical records and follow-ups. The study is expected to continue until August 2030.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
This research investigates patients who have experienced aneurysmal subarachnoid hemorrhage aSAH, a type of stroke caused by bleeding from a ruptured brain aneurysm. The study focuses on a complication called delayed ischemic neurological deficit DIND, which can lead to delayed cerebral ischemia and poor neurological outcomes despite early treatment. Researchers aim to understand how often DIND occurs, how it is diagnosed, and the treatments used across different centers, as well as the impact on patients recovery both short- and long-term. Participants include those diagnosed with aSAH, confirmed by imaging tests, who are admitted to intensive care. The study collects data on neurological symptoms and imaging to identify DIND and monitors instrumental methods like continuous EEG and ultrasound for diagnosis, especially in patients unable to be examined clinically. Researchers also observe various treatment approaches such as blood pressure management, local drug infusions, and mechanical interventions like angioplasty to compare their use and outcomes. During participation, patients undergo neurological examinations and imaging tests including CT and MRI to assess brain function and injury. Instrumental monitoring of intracranial pressure and cerebral blood flow is recorded to support diagnosis and management. The study follows patients for 12 months to measure the incidence of DIND and evaluate neurological and functional outcomes over time. Data on treatment intensity and monitoring usefulness are also collected to improve understanding of managing this condition.
1-10 of 19
1